Two drugs developed by Disc Medicine (IRON) and Sanofi (SNY) are facing delays in their review timelines due to safety and efficacy concerns in the U.S. after being selected for the FDA Commissioner’s ...

Good afternoon, everyone, and welcome to Morgan Stanley Global Healthcare Conference. I'm Sean Laaman, U.S. Head of SMid-Cap Biotech Equity Research here at the firm. Before we commence, for important ...

As of October 30, 2025, the average one-year price target for Disc Medicine is $111.09/share. The forecasts range from a low of $85.85 to a high of $160.65. The average price target represents an ...

Fintel reports that on August 22, 2024, Wells Fargo initiated coverage of Disc Medicine (NasdaqGM:IRON) with a Overweight recommendation. As of August 6, 2024, the average one-year price target for ...

We recently compiled a list of 10 Best Mid Cap Stocks to Buy According to Billionaires. Disc Medicine, Inc. stands sixth on our list and nears FDA filing for the first-ever EPP treatment. Disc ...

Hello, everyone. Welcome to Jefferies London Healthcare Conference 2025. My name is Roger Song, one of the senior analysts who covers mid-cap biotech in the U.S. It is my pleasure to have the fireside ...

Wells Fargo analyst Tiago Fauth maintained a Buy rating on Disc Medicine (IRON – Research Report) yesterday and set a price target of $91.00. The company’s shares closed yesterday at $58.25. According ...

Disc Medicine, Inc. (NASDAQ:IRON) is one of the 10 Best Small-Cap Growth Stocks to Buy According to Analysts. On June 11, analysts from Raymond James resumed coverage of Disc Medicine, Inc.